Striving for higher res imaging of cells, Harvard team debuts startup with backing from ARCH, Northpond – Endpoints News

By daniellenierenberg

When the tech VCs at Andreessen Horowitz entered biotech 4.5 years ago with the $200 million bio fund I, the idea was simple and hubristic: Were not going to do biotech, Vijay Pande said at the time, keeping a16zs longtime stance. Instead, the bio fund is really about funding software companies in the bio space.

In the near-half decade since, they havent softened their rhetoric. Pande and general partner Jorge Condes frequent blog posts often have the tone ofBurning Man technofuturists. Talking of a foundational shift in biology, bio-revolution, and the meaning of life, and dropping koans like what is medicine? has turned them into the well-financed New Age mystics of an AI-driven and bioengineered future.

Today, Andreessen Horowitz is launching bio fund III and putting $750 million behind it more than funds I and II combined. Theyve added new partners, as they did before fund I and II, picking up technologist and entrepreneur Julie Yoo and Vineeta Agarwala, a GV and Broad Institute alumn. Itll take much of the same tack as the earlier funds, investing early and occasionally up to Series B, and pouring funds not only into therapeutics, but also diagnostics, synthetic biology and startups bringing biological advances into other sectors, such as agriculture.

But Conde tells Endpoints News that the group has learned a thing or two since fund I. Pande had talked about extending Moores law to biology through digital therapeutics but they were wrong. It wasnt just about software and artificial intelligence. It was about the long list of ways how biology was done, how drugs were discovered and how the whole healthcare system functions. It was biotechs that worked both with machine learning and wet labs, and founders conversant in both.

Since then, theyve invested in companies like Insitro that integrate AI as a core but not sole part of a drug development chain and Asimov, which is trying to use AI and other tech systems to design a genome from scratch. They even invested in EQRx, Alexander Boriseys startup trying to use me-too drugs to change pricing.

In October, Conde, Pande and Yoo published their most soaring blog post yet: Biology is Eating the World: A Manifesto. They wrote: We are at the beginning of a new era, where biology has shifted from an empirical science to an engineering discipline.

Before the funds launch, though, Conde told Endpoints were at the end of the beginning for that era.

He talked about what theyve learned since bio I, where biology and biotech is headed and how well know when the convergence between engineering and biology hes been prophesizing has arrived.

You called this the end of the beginning for a new era. What does that mean?

Unlock this story instantly and join 71,300+ biopharma pros reading Endpoints daily and it's free.


Read more:
Striving for higher res imaging of cells, Harvard team debuts startup with backing from ARCH, Northpond - Endpoints News

Related Post

categoriaCardiac Stem Cells commentoComments Off on Striving for higher res imaging of cells, Harvard team debuts startup with backing from ARCH, Northpond – Endpoints News | dataFebruary 4th, 2020


This author published 1884 posts in this site.


FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.

Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research